# US 2022/0025372 A1 · Methods for treatment of polycystic kidney disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0025372 A1
- Document ID: US20220025372A1
- Status: Published application
- Kind: A1
- Application number: 17/494,234
- Filed: 2021-10-05
- Published: 2022-01-27
- Earliest claimed: 2015-08-26
- Assignees: Regulus Therapeutics Inc.; Board of Regents, The University of Texas System
- Applicants: Regulus Therapeutics Inc.; Board of Regents of The University of Texas System
- Inventors: John R. ANDROSAVICH; B. Nelson CHAU; Vishal D. PATEL
- Web page: https://patentgrep.com/patent/US20220025372A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/315: Phosphorothioates
- C12N 2310/322: 2'-R Modification
- C12N 2310/3231: having an additional ring, e.g. LNA, ENA
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.

## Claims

### Claim 1

A method of treating polycystic kidney disease comprising administering to a subject in need thereof a compound comprising a modified oligonucleotide consisting of 8 to 25 linked nucleosides, wherein the nucleobase sequence of the modified oligonucleotide is complementary to miR-17.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has polycystic kidney disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject is suspected of having polycystic kidney disease.

### Claim 4 (depends on 1)

The method of claim 1 wherein the subject has been diagnosed as having polycystic kidney disease prior to administering the modified oligonucleotide.

### Claim 5 (depends on 1)

The method of claim 1 wherein the subject, prior to administration of the modified oligonucleotide, was determined to have an increased level of miR-17 in the kidney, urine or blood of the subject.

### Claim 6 (depends on 1)

The method of claim 1, wherein the polycystic kidney disease is autosomal recessive polycystic kidney disease or autosomal dominant polycystic kidney disease.

### Claim 7 (depends on 1)

The method of claim 1, wherein the polycystic kidney disease is autosomal dominant polycystic kidney disease.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject has a mutation selected from a mutation in the PKD1 gene or a mutation in the PKD2 gene.

### Claim 9 (depends on 1)

The method of claim 1, wherein the subject has increased total kidney volume.

### Claim 10 (depends on 1)

The method of claim 1, wherein the subject has hypertension.

### Claim 11 (depends on 1)

The method of claim 1, wherein the subject has impaired kidney function.

### Claim 12 (depends on 1)

The method of claim 1, wherein the subject is in need of improved kidney function.

### Claim 13 (depends on 1)

The method of claim 1, wherein the administering:
a) improves kidney function in the subject;
b) delays the worsening of kidney function in the subject;
c) reduces total kidney volume in the subject;
d) slows the increase in total kidney volume in the subject;
e) inhibits cyst growth in the subject;
f) slows the increase in cyst growth in the subject;
g) reduces kidney pain in the subject;
h) slows the increase in kidney pain in the subject;
i) delays the onset of kidney pain in the subject;
j) reduces hypertension in the subject;
k) slows the worsening of hypertension in the subject;
l) delays the onset of hypertension in the subject;
m) reduces fibrosis in the kidney of the subject;
n) slows the worsening of fibrosis in the kidney of the subject;
o) delays the onset of end stage renal disease in the subject;
p) delays time to dialysis for the subject;
q) delays time to renal transplant for the subject; and/or
r) improves life expectancy of the subject.

### Claim 14 (depends on 1)

The method of claim 1, wherein the administering:
s) reduces albuminuria in the subject;
t) slows the worsening of albuminuria in the subject;
u) delays the onset of albuminuria in the subject;
v) reduces hematuria in the subject;
w) slows the worsening of hematuria in the subject;
x) delays the onset of hematuria in the subject;
y) reduces blood urea nitrogen in the subject;
z) reduces creatinine in the blood of the subject;
aa) improves creatinine clearance in the subject;
bb) reduces albumin:creatinine ratio in the subject;
cc) improves glomerular filtration rate in the subject;
dd) slows the worsening of glomerular filtration rate in the subject;
ee) reduces neutrophil gelatinase-associated lipocalin (NGAL) protein in the urine of the subject; and/or
ff) reduces kidney injury molecule-1 (KIM-1) protein in the urine of the subject.

### Claim 15 (depends on 1)

The method of claim 1, comprising:
gg) measuring total kidney volume in the subject;
hh) measuring hypertension in the subject;
ii) measuring kidney pain in the subject;
jj) measuring fibrosis in the kidney of the subject;
kk) measuring blood urea nitrogen in the blood of the subject;
ll) measuring creatinine in the blood of the subject;
mm) measuring creatinine clearance in the subject;
nn) measuring albuminuria in the subject;
oo) measuring albumin:creatinine ratio in the subject;
pp) measuring glomerular filtration rate in the subject;
qq) measuring neutrophil gelatinase-associated lipocalin (NGAL) protein in the urine of the subject; and/or
rr) measuring kidney injury molecule-1 (KIM-1) protein in the urine of the subject.

### Claim 16 (depends on 9)

The method of claim 9, wherein the total kidney volume is height-adjusted kidney volume.

### Claim 17 (depends on 13)

The method of claim 13, wherein the cyst is present in one or more kidneys in the subject.

### Claim 18 (depends on 13)

The method of claim 13, wherein the cyst is present in the liver of the subject.

### Claim 19 (depends on 1)

The method of claim 1, comprising administering at least one additional therapy that is an anti-hypertensive agent.

### Claim 20 (depends on 1)

The method of claim 1, comprising administering at least one additional therapy selected from an angiotensin II converting enzyme (ACE) inhibitor, an angiotensin II receptor blocker (ARB), a diuretic, a calcium channel blocker, a kinase inhibitor, an adrenergic receptor antagonist, a vasodilator, a benzodiazepine, a renin inhibitor, an aldosterone receptor antagonist, an endothelin receptor blocker, an mammalian target of rapamycin (mTOR) inhibitor, a hormone analogue, a vasopressin receptor 2 antagonist, an aldosterone receptor antagonist, dialysis, and kidney transplant.

### Claim 21 (depends on 20)

The method of claim 20 wherein the angiotensin II converting enzyme (ACE) inhibitor is selected from captopril, enalapril, lisinopril, benazepril, quinapril, fosinopril, and ramipril.

### Claim 22 (depends on 20)

The method of claim 20 wherein the angiotensin II receptor blocker (ARB) is selected from candesartan, irbesartan, olmesartan, losartan, valsartan, telmisartan, and eprosartan.

### Claim 23 (depends on 20)

The method of claim 20 wherein the vasopressin receptor 2 antagonist is tolvaptan.

### Claim 24 (depends on 20)

The method of claim 20, wherein the aldosterone receptor antagonist is spironolactone.

### Claim 25 (depends on 20)

The method of claim 20, wherein the kinase inhibitor is selected from bosutinib and KD019.

### Claim 26 (depends on 20)

The method of claim 20, wherein the mTOR inhibitor is selected from everolimus, rapamycin, and sirolimus.

### Claim 27 (depends on 20)

The method of claim 20, the hormone analogue is selected from somatostatin and adrenocorticotrophic hormone.

### Claim 28 (depends on 1)

The method of claim 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 90% complementary, is at least 95% complementary, or is 100% complementary to the nucleobase sequence of miR-17 (SEQ ID NO: 1).

### Claim 29 (depends on 1)

The method of claim 1, wherein the nucleobase sequence of the modified oligonucleotide comprises the nucleobase sequence 5′-GCACTTTG-3′ (SEQ ID NO: 3), wherein each T in the nucleobase sequence is independently selected from a T and a U.

### Claim 30 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide consists of 8 to 12 linked nucleosides.

### Claim 31 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide consists of 12 to 25 linked nucleosides.

### Claim 32 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide consists of 15 to 25 linked nucleosides.

### Claim 33 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide consists of 17 to 23 linked nucleosides.

### Claim 34 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide consists of 8, 9, 10, 11 or 12 linked nucleosides.

### Claim 35 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide consists of 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 linked nucleosides.

### Claim 36 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide consists of 15, 16, 17, 18, 19, 20, 21, or 22 linked nucleosides.

### Claim 37 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide consists of 17, 18, 19, 20, 21, 22, or 23 linked nucleosides.

### Claim 38 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide comprises at least one modified nucleoside.

### Claim 39 (depends on 38)

The method of claim 38, wherein the modified nucleoside is selected from an S-cEt nucleoside, a 2′-O-methoxyethyl nucleoside, and an LNA nucleoside.

### Claim 40 (depends on 1)

The method of claim 1, wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.

### Claim 41 (depends on 1)

The method of claim 1, wherein each internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage.

### Claim 42 (depends on 40)

The method of claim 40, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.

### Claim 43 (depends on 1)

The method of claim 1, wherein the compound consists of the modified oligonucleotide.

### Claim 44 (depends on 1)

The method of claim 1, comprising administering a therapeutically effective amount of the compound.

### Claim 45

(canceled)
